AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
The Source
CNBC
Business
RFK Jr. says cyclospora outbreak is ‘under control’
CNBC·1h ago·3 min read
US
$100M New Jersey deli fraudster James Patten sentenced to 21 months in prison
CNBC·1h ago·3 min read
Business
Goldman Sachs creates private markets platform as rich investors seek the next SpaceX and Stripe
CNBC·2h ago·3 min read
Health
Cardinal Health’s latest deals won’t move the needle overnight. They still matter.
CNBC·3h ago·3 min read
Related
On this beat
Health
Cardinal Health’s latest deals won’t move the needle overnight. They still matter.
CNBC·3h ago·3 min read
Health
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
CNBC·5h ago·3 min read
Health
1,700 H.I.V. Treatment Sites Closed After Trump Aid Cuts, a Study Finds
TNYT·6h ago·3 min read
Health
Smash Chicken Caesar Tacos
WELNESS MAMA·6h ago·3 min read